| 摘要 |
Use of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, as an inhibitor of at least one beta-ketoacyl acyl carrier protein synthase operable in the fatty acid biosynthesis of endoparasites, which compound is of the general formula (I) where R1 is selected from the group consisting of hydrogen, alkyl, (cyano)alkylene, alkenyl, alkynyl, (alkoxy)alkylene, (alkoxy)alkenylene, (alkoxy)alkynylene, cycloalkyl, (cycloalkyl)alkylene, (cycloalkyl)alkenylene, (cycloalkyl)alkynylene, (hetero-cycle)alkylene, (heterocycle)alkenylene, (heterocycle)alkynylene, aryl, (aryl)alkylene, (aryl)alkenylene, (aryl)alkynylene, (arylcarbonylarylene)alkylene, (arylcarbonylarylene)alkenylene and (arylcarbonylarylene)alkynylene; R2 is alkyl or cycloalkyl; R3 is alkyl or cycloalkyl; and R4 is hydrogen or alkyl; including racemic mixtures and enantiomers of said compound when the latter is chiral, but excluding the racemic mixture of a chiral compound of formula (I) in which R1 is CH2=CH-C(CH3)=CH-, R2 is methyl, R3 is methyl and R4 is hydrogen.
|
